Suleman, M.; Arbab, H.; Yassine, H.M.; Sayaf, A.M.; Ilahi, U.; Alissa, M.; Alghamdi, A.; Alghamdi, S.A.; Crovella, S.; Shaito, A.A.
Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target. Pharmaceuticals 2025, 18, 1144.
https://doi.org/10.3390/ph18081144
AMA Style
Suleman M, Arbab H, Yassine HM, Sayaf AM, Ilahi U, Alissa M, Alghamdi A, Alghamdi SA, Crovella S, Shaito AA.
Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target. Pharmaceuticals. 2025; 18(8):1144.
https://doi.org/10.3390/ph18081144
Chicago/Turabian Style
Suleman, Muhammad, Hira Arbab, Hadi M. Yassine, Abrar Mohammad Sayaf, Usama Ilahi, Mohammed Alissa, Abdullah Alghamdi, Suad A. Alghamdi, Sergio Crovella, and Abdullah A. Shaito.
2025. "Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target" Pharmaceuticals 18, no. 8: 1144.
https://doi.org/10.3390/ph18081144
APA Style
Suleman, M., Arbab, H., Yassine, H. M., Sayaf, A. M., Ilahi, U., Alissa, M., Alghamdi, A., Alghamdi, S. A., Crovella, S., & Shaito, A. A.
(2025). Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target. Pharmaceuticals, 18(8), 1144.
https://doi.org/10.3390/ph18081144
